Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Analysis on the Research Progress of Neprilysin Inhibitor
Analysis on the Research Progress of Neprilysin Inhibitor
18 October 2023
Neprilysin, also known as membrane metallo-endopeptidase (MME), neutral endopeptidase (NEP), cluster of differentiation 10 (CD10), and common acute lymphoblastic leukemia antigen (CALLA) is an enzyme that in humans is encoded by the MME gene.
Read →
Janssen applies to European Medicines Agency for approval to use RYBREVANT (amivantamab) plus chemotherapy for newly diagnosed advanced NSCLC patients with EGFR Exon 20 Insertion Mutations
Latest Hotspot
3 min read
Janssen applies to European Medicines Agency for approval to use RYBREVANT (amivantamab) plus chemotherapy for newly diagnosed advanced NSCLC patients with EGFR Exon 20 Insertion Mutations
18 October 2023
Janssen applies to the European Medicines Agency, seeking approval for using RYBREVANT (amivantamab) combined with chemotherapy to treat adults initially diagnosed with late-stage Non-Small Cell Lung Cancer with proficient EGFR Exon 20 Insertion Mutations.
Read →
Deep Scientific Insights on interferon beta-1b's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on interferon beta-1b's R&D Progress, Mechanism of Action, and Drug Target
18 October 2023
This article summarized the latest R&D progress of interferon beta-1b, the Mechanism of Action for interferon beta-1b, and the drug target R&D trends for interferon beta-1b.
Read →
Latest Competitive Analysis of AbbVie Drug Pipeline
R&D Pipeline
2 min read
Latest Competitive Analysis of AbbVie Drug Pipeline
18 October 2023
Since acquiring Allergan, AbbVie has experienced a period of stable performance, but this year has seen a significant decline in the performance of its two heavyweight drugs, Adalimumab and Ibrutinib.
Read →
 An In-depth Analysis of itopride hydrochloride's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
5 min read
An In-depth Analysis of itopride hydrochloride's R&D Progress and Mechanism of Action on Drug Target
18 October 2023
This article summarized the latest R&D progress of itopride hydrochloride, the Mechanism of Action for itopride hydrochloride, and the drug target R&D trends for itopride hydrochloride
Read →
Rivus Pharmaceuticals' HU6 2a trial showed positive outcomes in treating high BMI individuals with Non-alcoholic Fatty Liver Disease
Latest Hotspot
3 min read
Rivus Pharmaceuticals' HU6 2a trial showed positive outcomes in treating high BMI individuals with Non-alcoholic Fatty Liver Disease
18 October 2023
The 2a trial of Rivus Pharmaceuticals' experimental metabolic booster, HU6, yielded promising results in treating High BMI individuals with Non-alcoholic Fatty Liver Disease.
Read →
 laquinimod: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
Drug Insights
4 min read
laquinimod: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
18 October 2023
This article summarized the latest R&D progress of laquinimod, the Mechanism of Action for laquinimod, and the drug target R&D trends for laquinimod.
Read →
Finding the Complete Antibody Sequence Using a Known CDR Sequence: An Exploration with Patsnap Bio Sequence Database
Bio Sequence
2 min read
Finding the Complete Antibody Sequence Using a Known CDR Sequence: An Exploration with Patsnap Bio Sequence Database
18 October 2023
One can elucidate the entire antibody sequence by utilizing a known Complementarity-determining region (CDR) sequence in combination with the accessible Patsnap Bio Sequence Database.
Read →
Latest Competitive Analysis of Merck Sharp & Dohme Drug Pipeline
R&D Pipeline
2 min read
Latest Competitive Analysis of Merck Sharp & Dohme Drug Pipeline
18 October 2023
Merck's recent revenue performance remains steady, with the K drug continuing to grow and earning the title of "New Generation Drug King".
Read →
Avidity Biosciences presents encouraging results for AOC 1001, showing progress and long-term safety in multiple areas for Type 1 Myotonic Dystrophy patients
Latest Hotspot
4 min read
Avidity Biosciences presents encouraging results for AOC 1001, showing progress and long-term safety in multiple areas for Type 1 Myotonic Dystrophy patients
18 October 2023
Avidity Biosciences Reports Fresh Positive Results for AOC 1001, Showing Progress in Various Additional Functional Measures and Long-term Safety and Acceptability in Individuals with Type 1 Myotonic Dystrophy.
Read →
Reducing the Risk of FTO Missed Detection in Special Referential Sequences of Patents
Bio Sequence
2 min read
Reducing the Risk of FTO Missed Detection in Special Referential Sequences of Patents
18 October 2023
The patent and literature contain sequences of nucleic acids containing N and protein sequences containing X. I'm interested in reducing the risk of missing such sequences. Is there a recommended database where I can search for these sequences?
Read →
Epalrestat Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
5 min read
Epalrestat Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
18 October 2023
This article summarized the latest R&D progress of epalrestat, the Mechanism of Action for epalrestat, and the drug target R&D trends for epalrestat.
Read →